Heart Failure Clinical Trials in Milwaukee, Wisconsin

13 studies are recruiting for heart failure in Milwaukee, Wisconsin right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

   Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

   Stage

   Phase 3

   Ages

   40 and older

   Site

   Research Site, Milwaukee, Wisconsin

   Locations

   957 in total

   Run by

   AstraZeneca

   See if you can join NCT06677060 on ClinicalTrials.gov

2. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

   Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Milwaukee, WI Investigative Site 10061, Milwaukee, Wisconsin

   Locations

   356 in total

   Run by

   Colorado Prevention Center

   See if you can join NCT06008197 on ClinicalTrials.gov

3. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

   The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

   Stage

   Not phased

   Ages

   18 to 100

   Site

   Aurora St. Luke's Medical Center, Milwaukee, Wisconsin

   Locations

   47 in total

   Run by

   BrioHealth Solutions, Inc.

   See if you can join NCT06310031 on ClinicalTrials.gov

4. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

   The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   Medical College of Wisconsin / Froedtert Hospital, Milwaukee, Wisconsin

   Locations

   205 in total

   Run by

   Cytokinetics

   See if you can join NCT06736574 on ClinicalTrials.gov

5. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

   The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

   Stage

   Not phased

   Ages

   0 to 20

   Site

   Medical College of Wisconsin, Milwaukee, Wisconsin

   Locations

   52 in total

   Run by

   Duke University

   See if you can join NCT04278404 on ClinicalTrials.gov

6. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

   The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

   Stage

   Not phased

   Ages

   Any age

   Site

   Research site, Milwaukee, Wisconsin

   Locations

   333 in total

   Run by

   Medtronic

   See if you can join NCT00271180 on ClinicalTrials.gov

7. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Aurora St. Luke's Medi Ctr, Milwaukee, Wisconsin

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

8. Alleviant ALLAY-HF Study

   Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

   Stage

   Not phased

   Ages

   40 and older

   Site

   Advocate Aurora Health/Aurora Research Institute, Milwaukee, Wisconsin

   Locations

   93 in total

   Run by

   Alleviant Medical, Inc.

   See if you can join NCT05685303 on ClinicalTrials.gov

9. A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

   Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Milwaukee, WI Investigative Site FIN-10428, Milwaukee, Wisconsin

   Locations

   176 in total

   Run by

   Colorado Prevention Center

   See if you can join NCT06033950 on ClinicalTrials.gov

10. PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

    This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate saf…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Advocate Aurora St. Luke's, Milwaukee, Wisconsin

    Locations

    48 in total

    Run by

    Endotronix, Inc.

    See if you can join NCT05934487 on ClinicalTrials.gov

11. Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

    The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Aurora Medical Group, Milwaukee, Wisconsin

    Locations

    68 in total

    Run by

    Abbott Medical Devices

    See if you can join NCT06526195 on ClinicalTrials.gov

12. CCM OPEN HF Registry

    The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Advocate Aurora Health-St. Lukes, Milwaukee, Wisconsin

    Locations

    28 in total

    Run by

    Impulse Dynamics

    See if you can join NCT07112924 on ClinicalTrials.gov

13. The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

    The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Advocate Aurora Research Institute, Milwaukee, Wisconsin

    Locations

    92 in total

    Run by

    Cardiac Dimensions, Inc.

    See if you can join NCT03142152 on ClinicalTrials.gov